Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12267730 | 0.91 | MME (0.33) | TSHRMMETNFMMP1MMP2 | |
| SCHEMBL18254442 | 0.85 | TSHR (0.36) | TSHRCYP3A4ATMTDP1RECQL | |
| SCHEMBL22238278 | 0.85 | CYP3A4 (0.42) | TSHRCYP3A4ATMTDP1RECQL | |
| SCHEMBL12707569 | 0.80 | TSHR (0.32) | TSHRCYP3A4ATMTDP1RECQL | |
| SCHEMBL12015497 | 0.79 | TSHR (0.43) | TSHRCYP3A4TDP1ALDH1A1ADAM17 | |
| SCHEMBL12267797 | 0.78 | TSHR (0.37) | TSHRCYP3A4ATMTDP1RECQL | |
| SCHEMBL22238311 | 0.76 | MAPT (0.39) | TSHRTNFMMP1MMP2MMP3 | |
| SCHEMBL15443271 | 0.75 | ALDH1A1 (0.40) | TSHRCYP3A4TRPA1ALDH1A1 | |
| SCHEMBL20221807 | 0.75 | ALDH1A1 (0.40) | TSHRCYP3A4TRPA1ALDH1A1 | |
| SCHEMBL12267751 | 0.75 | PRKCA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9289503-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9278136-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9238077-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9150504-B2 | Fatty acid guanidine and salicylate guanidine derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150238618-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-9029548-B2 | Fatty acid lenalidomide derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140249189-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140228413-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130190327-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2013-07-25 | — | — | US | disclosed |
| US-20120283292-A1 | FATTY ACID LENALIDOMIDE AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20110213028-A1 | FATTY ACID MYCOPHENOLATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212958-A1 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | TSHR 2965/4885CYP3A4 2263/4885ATM 4822/4885 |
| US-20140228413-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | TSHR 1309/4885CYP3A4 1186/4885ATM 4340/4885 |
| US-20150238618-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | TSHR 4367/4885CYP3A4 2336/4885ATM 2721/4885 |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | TSHR 2741/4885CYP3A4 1724/4885ATM 4145/4885 |
| US-20140249189-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | TSHR 1309/4885CYP3A4 1186/4885ATM 4340/4885 |
| US-20110212958-A1 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES | ELOVL5, ELOVL3, ELOVL6 | TSHR 1261/4885CYP3A4 1071/4885ATM 4082/4885 |
| US-20130190327-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | FASN, ELOVL1, ELOVL5 | TSHR 3076/4885CYP3A4 2411/4885ATM 4051/4885 |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | SCD, SCD5, FASN | TSHR 3580/4885CYP3A4 2705/4885ATM 3143/4885 |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | NAMPT, NNT, FASN | TSHR 1312/4885CYP3A4 1716/4885ATM 4252/4885 |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | TSHR 2965/4885CYP3A4 2263/4885ATM 4822/4885 |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | TSHR 4367/4885CYP3A4 2336/4885ATM 2721/4885 |
| US-20120283292-A1 | FATTY ACID LENALIDOMIDE AND THEIR USES | ELOVL1, FASN, FFAR2 | TSHR 1105/4885CYP3A4 1457/4885ATM 4419/4885 |
| US-20110213028-A1 | FATTY ACID MYCOPHENOLATE DERIVATIVES AND THEIR USES | FABP1, FFAR4, FABP3 | TSHR 1372/4885CYP3A4 264/4885ATM 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.